IBRX

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Immunitybio Inc

NASDAQ | IBRX

2.36

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 28, 2025)

$2.32B

Market Cap

-

P/E Ratio

-0.41

EPS

$5.12

52 Week High

$1.83

52 Week Low

HEALTHCARE

Sector

IBRX Chart

Recent Chart
Price Action

IBRX Technicals

Tags:

IBRX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $15M
Total Revenue $15M
Cost Of Revenue $18M
Costof Goods And Services Sold $18M
Operating Income -$344M
Selling General And Administrative $169M
Research And Development $190M
Operating Expenses $359M
Investment Income Net -
Net Interest Income -$152M
Interest Income $2.4M
Interest Expense $132M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $18M
Income Before Tax -$414M
Income Tax Expense $81K
Interest And Debt Expense -
Net Income From Continuing Operations -$414M
Comprehensive Income Net Of Tax -
Ebit -$282M
Ebitda -$264M
Net Income -$414M

Revenue & Profitability

Earnings Performance

IBRX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $383M
Total Current Assets $185M
Cash And Cash Equivalents At Carrying Value $143M
Cash And Short Term Investments $143M
Inventory $8.3M
Current Net Receivables $2.7M
Total Non Current Assets $198M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $16M
Intangible Assets Excluding Goodwill $16M
Goodwill $910K
Investments -
Long Term Investments $0
Short Term Investments $6.4M
Other Current Assets $24M
Other Non Current Assets -
Total Liabilities $871M
Total Current Liabilities $55M
Current Accounts Payable $6.7M
Deferred Revenue -
Current Debt -
Short Term Debt $7.5M
Total Non Current Liabilities $816M
Capital Lease Obligations $42M
Long Term Debt $462M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $504M
Other Current Liabilities $41M
Other Non Current Liabilities $285M
Total Shareholder Equity -$489M
Treasury Stock -
Retained Earnings -$3.4B
Common Stock $85K
Common Stock Shares Outstanding $700M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$391M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $18M
Capital Expenditures $6.9M
Change In Receivables -
Change In Inventory -$8.3M
Profit Loss -
Cashflow From Investment -$12M
Cashflow From Financing $282M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$414M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $15M
Total Revenue $15M
Cost Of Revenue $18M
Costof Goods And Services Sold $18M
Operating Income -$344M
Selling General And Administrative $169M
Research And Development $190M
Operating Expenses $359M
Investment Income Net -
Net Interest Income -$152M
Interest Income $2.4M
Interest Expense $132M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $18M
Income Before Tax -$414M
Income Tax Expense $81K
Interest And Debt Expense -
Net Income From Continuing Operations -$414M
Comprehensive Income Net Of Tax -
Ebit -$282M
Ebitda -$264M
Net Income -$414M

IBRX News

IBRX Profile

Immunitybio Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

ImmunityBio, Inc. is an innovative immunotherapy company dedicated to developing groundbreaking treatments that harness the power of memory T-cells for the fight against various cancers. The company's proprietary cancer vaccine represents a paradigm shift in oncology, aiming to optimize therapeutic efficacy while reducing dependence on high-dose chemotherapy. Through its cutting-edge biotechnology platform, ImmunityBio is poised to redefine cancer treatment paradigms, enhance patient outcomes, and establish itself as a leader in the rapidly changing landscape of cancer therapeutics.

LPTX
+368.57%
$2.05
HBI
-1.82%
$6.47
VINE
+21.21%
$0.48
TLRY
-21.06%
$0.81
QTTB
+153.42%
$5.54
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
BYND
-3.74%
$0.98
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
ADAP
-15.14%
$0.05
IVP
+8.86%
$0.13
SOND
-23.45%
$0.12
NVDA
+0.80%
$178.42
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
ONMD
+30.28%
$1.85
CHR
+13.49%
$0.04
BURU
+9.84%
$0.24
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
SOFI
+4.31%
$29.72
BTBT
+2.58%
$2.38
ADTX
+21.01%
$3.80
AFMD
-34.94%
$0.18
CRCL
+10.03%
$79.93
KWM
+13.63%
$0.75
IBRX
+10.79%
$2.36
RIOT
+7.82%
$16.13
BITF
-5.60%
$3.28
INTC
-2.00%
$39.74
AMZN
+1.77%
$233.22
AIIO
-9.09%
$0.70
NWTN
-9.09%
$0.70
APLD
+8.66%
$27.10
GOOG
-0.05%
$320.12
IREN
-1.32%
$47.81
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
ASST
-6.25%
$1.05
AMC
+6.52%
$2.45
VHAI
-25.00%
$0.00
SNAP
-1.43%
$7.56
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
MSFT
+1.34%
$492.01
CLSK
-3.50%
$14.57
BMNR
-8.57%
$30.28
CRWV
-1.57%
$73.12
SHOT
-74.37%
$0.39
VIVK
-5.32%
$0.12
NIO
-4.63%
$5.24
ONDS
-1.01%
$7.82
ZAPP
-46.30%
$0.15
SNDK
+3.83%
$223.28
ABVE
+14.06%
$3.00
INHD
-12.16%
$0.19
BMNU
-15.39%
$6.92
SOUN
+1.94%
$12.05
RUBI
-13.53%
$0.13
IONQ
+5.11%
$49.30
WBUY
+24.68%
$1.97
WMT
+1.29%
$110.51
DRCT
-21.52%
$0.11
F
+0.39%
$13.33
QUBT
+2.09%
$11.70
OMC
+0.16%
$71.62
KVUE
+0.75%
$17.35
COIN
+2.96%
$272.82
IQ
+1.86%
$2.19
MARA
-4.40%
$11.29
GME
+4.16%
$22.53
KDLY
+0.36%
$0.50
GPUS
-7.80%
$0.27
WULF
-1.22%
$15.32
PLUG
-2.76%
$1.95
RIVN
+3.52%
$17.45
VGFC
-1.90%
$0.05
CAN
-9.31%
$0.91
AAL
-0.74%
$13.94
DVLT
-8.30%
$1.86
PLTR
-0.78%
$167.13
SVMH
-14.58%
$0.73
MOS
+0.94%
$24.49
SPGC
-8.21%
$0.16
FI
+1.10%
$61.47
AG
+2.19%
$15.56
SKYQ
+15.27%
$0.40
TGI
+0.61%
$26.01
TGB
+4.76%
$5.28
DIS
+1.00%
$104.47
NAYA
+10.96%
$2.24
CIFR
-1.42%
$20.06
STNE
+5.77%
$16.85
FNGB
+2.90%
$21.28
XP
+3.24%
$19.71
LPTX
+368.57%
$2.05
HBI
-1.82%
$6.47
VINE
+21.21%
$0.48
TLRY
-21.06%
$0.81
QTTB
+153.42%
$5.54
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
BYND
-3.74%
$0.98
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
ADAP
-15.14%
$0.05
IVP
+8.86%
$0.13
SOND
-23.45%
$0.12
NVDA
+0.80%
$178.42
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
ONMD
+30.28%
$1.85
CHR
+13.49%
$0.04
BURU
+9.84%
$0.24
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
SOFI
+4.31%
$29.72
BTBT
+2.58%
$2.38
ADTX
+21.01%
$3.80
AFMD
-34.94%
$0.18
CRCL
+10.03%
$79.93
KWM
+13.63%
$0.75
IBRX
+10.79%
$2.36
RIOT
+7.82%
$16.13
BITF
-5.60%
$3.28
INTC
-2.00%
$39.74
AMZN
+1.77%
$233.22
AIIO
-9.09%
$0.70
NWTN
-9.09%
$0.70
APLD
+8.66%
$27.10
GOOG
-0.05%
$320.12
IREN
-1.32%
$47.81
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
ASST
-6.25%
$1.05
AMC
+6.52%
$2.45
VHAI
-25.00%
$0.00
SNAP
-1.43%
$7.56
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
MSFT
+1.34%
$492.01
CLSK
-3.50%
$14.57
BMNR
-8.57%
$30.28
CRWV
-1.57%
$73.12
SHOT
-74.37%
$0.39
VIVK
-5.32%
$0.12
NIO
-4.63%
$5.24
ONDS
-1.01%
$7.82
ZAPP
-46.30%
$0.15
SNDK
+3.83%
$223.28
ABVE
+14.06%
$3.00
INHD
-12.16%
$0.19
BMNU
-15.39%
$6.92
SOUN
+1.94%
$12.05
RUBI
-13.53%
$0.13
IONQ
+5.11%
$49.30
WBUY
+24.68%
$1.97
WMT
+1.29%
$110.51
DRCT
-21.52%
$0.11
F
+0.39%
$13.33
QUBT
+2.09%
$11.70
OMC
+0.16%
$71.62
KVUE
+0.75%
$17.35
COIN
+2.96%
$272.82
IQ
+1.86%
$2.19
MARA
-4.40%
$11.29
GME
+4.16%
$22.53
KDLY
+0.36%
$0.50
GPUS
-7.80%
$0.27
WULF
-1.22%
$15.32
PLUG
-2.76%
$1.95
RIVN
+3.52%
$17.45
VGFC
-1.90%
$0.05
CAN
-9.31%
$0.91
AAL
-0.74%
$13.94
DVLT
-8.30%
$1.86
PLTR
-0.78%
$167.13
SVMH
-14.58%
$0.73
MOS
+0.94%
$24.49
SPGC
-8.21%
$0.16
FI
+1.10%
$61.47
AG
+2.19%
$15.56
SKYQ
+15.27%
$0.40
TGI
+0.61%
$26.01
TGB
+4.76%
$5.28
DIS
+1.00%
$104.47
NAYA
+10.96%
$2.24
CIFR
-1.42%
$20.06
STNE
+5.77%
$16.85
FNGB
+2.90%
$21.28
XP
+3.24%
$19.71
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.